Radioligand Therapies Market Expected To Witness Significant Growth By 2036, Driven By Rising Cancer Burden, Precision Oncology, And Expansion Of Next-Generation Radioligand Therapies Delveinsight

DelveInsight's latest report,“Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast,” provides a comprehensive analysis of the radioligand therapies market across the United States, EU4, the United Kingdom, and Japan. The report provides insights into the current and emerging radioligand therapy landscape, historical and forecasted market trends, target patient populations, competitive landscape, treatment practices, and market opportunities through 2036.

(Albany, New York)- 10th Sep 2026 - DelveInsight's latest report,“Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2036,” provides a comprehensive analysis of the radioligand therapies market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report provides insights into the current and emerging radioligand therapy landscape, historical and forecasted market trends, target patient populations, competitive landscape, treatment practices, and market opportunities through 2036.

Radioligand therapy is an emerging precision oncology approach that combines a radioactive isotope with a target-seeking ligand to selectively deliver radiation to cancer cells expressing specific molecular targets. The increasing global cancer burden, growing demand for targeted therapies, expansion of clinical trials, and rising investment by major pharmaceutical companies are expected to support significant growth of the radioligand therapies market during the forecast period.

Key Takeaways from the Radioligand Therapies Market

• The radioligand therapies market is expected to grow rapidly through 2036, supported by increasing adoption of targeted nuclear medicine and the expansion of the clinical pipeline.

• LUTATHERA recorded more than USD 450 million in sales during the first nine months of 2023, representing a 34% year-over-year growth rate, while Novartis expects the therapy could achieve more than USD 1 billion in peak sales as a first-line therapy.

• PLUVICTO generated approximately USD 980 million in full-year sales in 2022, following its approval, demonstrating the commercial potential of targeted radioligand therapies.

• The current marketed radioligand therapy landscape includes LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN.

• The pipeline includes several next-generation radioligand therapies targeting indications such as metastatic castration-resistant prostate cancer (mCRPC), gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and other solid tumors.

• Key emerging therapies include 177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, 225Ac-PSMA-617, 177Lu-NNS309, 177Lu-NeoB, ITM-11, CONV01-α, VMT-α-NET, VMT01, CAM-FAP-Ac-225, and others.

• Leading companies developing radioligand therapies include Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, Nuclidium, and others.

Keen to know more about the Radioligand Therapies Market Report?

Key Factors Driving the Radioligand Therapies Market

Rising Global Cancer Burden

The increasing prevalence of cancers, particularly prostate cancer and neuroendocrine tumors, is a major factor driving demand for radioligand therapies. These therapies offer a targeted treatment approach for patients with advanced cancers that may be difficult to manage using conventional chemotherapy or external radiation.

Growing Demand for Targeted and Precision Oncology

Radioligand therapies represent an important advancement in precision oncology by combining a target-specific ligand with a therapeutic radioisotope. The ligand binds to specific proteins or receptors expressed on cancer cells, allowing radiation to be delivered directly to tumor sites while potentially limiting damage to surrounding healthy tissues.

Increasing Clinical Trial Activities

The radioligand therapy pipeline is expanding rapidly, with numerous candidates being evaluated across Phase I, Phase II, and Phase III clinical trials. Several therapies are being developed for prostate cancer, GEP-NETs, and other difficult-to-treat solid tumors, creating significant opportunities for market expansion.

Growing Potential of Next-generation Radioligand Therapies

The development of next-generation radioligand therapies using different radioisotopes and molecular targets is expected to broaden the therapeutic applications of RLT. Candidates such as 177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, and CONV01-α demonstrate the increasing focus on improving targeting, efficacy, and treatment options for patients with advanced disease.

Increasing Strategic Investments and Collaborations

Major pharmaceutical companies are increasingly investing in the radiopharmaceutical space through acquisitions, licensing agreements, and research collaborations. For example, Eli Lilly completed its acquisition of Point Biopharma for approximately USD 1.4 billion in July 2024, strengthening its position in the radioligand therapy landscape.

Competitive Landscape

The radioligand therapies market includes established marketed products and a rapidly expanding pipeline of emerging therapies.

Currently marketed radioligand therapies include LUTATHERA (lutetium Lu 177 dotatate) from Novartis, PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) from Novartis, XOFIGO (radium Ra 223 dichloride) from Bayer, and ZEVALIN (ibritumomab tiuxetan) from Spectrum Pharmaceuticals.

Among emerging therapies, 177Lu-PSMA-I&T from Curium is being evaluated for mCRPC, while Lu-PNT2002 from Eli Lilly/Point Biopharma is a PSMA-targeted lutetium-177 radioligand therapy candidate. FPI-2265 from Fusion Pharmaceuticals/AstraZeneca is another emerging radioligand therapy being evaluated for mCRPC.

Other companies with significant pipeline activity include Novartis, Lantheus, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, and Nuclidium.

Recent Developments in the Radioligand Therapies Market

• March 2026: ITM Isotope Technologies Munich SE presented post-hoc subgroup analyses from the Phase III ITM-11 COMPETE trial involving patients with Grade 1 or Grade 2 somatostatin receptor-positive GEP-NETs.

• March 2026: Lantheus Holdings announced that the FDA granted tentative approval to its ANDA for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of LUTATHERA.

• January 2026: Zonsen PepLib Biotech announced a global licensing agreement with Novartis for an undisclosed peptide-based radioligand therapy candidate, with Novartis securing exclusive worldwide rights.

• January 2026: Swiss Rockets AG and Alloy Therapeutics entered into a Master Research Agreement focused on discovering and developing next-generation radioligand therapeutics.

• January 2026: ARTBIO began dosing two US-based patient cohorts in the ARTISAN Phase I trial of AB001, an alpha radioligand therapy for metastatic castration-resistant prostate cancer.

• November 2025: ITM Isotope Technologies announced that the FDA had accepted its NDA for n.c.a. 177Lu-edotreotide (ITM-11).

• ASCO 2026: Convergent Therapeutics reported interim Phase II results for CONV01-α, demonstrating a 40% PSA response rate (≥50% decline) and median radiographic progression-free survival of 8.4 months at the target dose in patients with mCRPC previously treated with Lu-177-PSMA therapy.

What are Radioligand Therapies?

Radioligand therapies are a form of targeted nuclear medicine designed to recognize and treat cancer cells expressing specific molecular targets. They combine two primary components: a radioisotope and a cell-targeting compound or ligand.

The ligand binds to a specific protein or receptor expressed on cancer cells and directs the radioactive isotope to those cells. Following administration, typically through intravenous infusion, the radioligand circulates through the bloodstream and binds to its target. The radioisotope then emits radiation that damages the DNA of cancer cells, leading to their destruction while limiting exposure to surrounding healthy tissue.

Radioligand therapies have demonstrated clinical utility in cancers such as GEP-NETs and metastatic castration-resistant prostate cancer, while ongoing research is evaluating their potential across additional tumor types, including aggressive and rare cancers.

Current Treatment Landscape

The radioligand therapy landscape currently includes approved products such as LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN. LUTATHERA is used for somatostatin receptor-positive GEP-NETs, while PLUVICTO is approved for eligible patients with PSMA-positive mCRPC. XOFIGO is used in patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease, while ZEVALIN is indicated for selected patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

The emerging landscape includes therapies targeting PSMA, somatostatin receptors, and other tumor-associated targets, with candidates employing both beta- and alpha-emitting radioisotopes. Increasing clinical development activity is expected to expand the role of radioligand therapy in precision oncology.

Radioligand Therapies Epidemiology Segmentation

The radioligand therapies epidemiology analysis covers:

• Total Cases of Selected Indications for Radioligand Therapies in the 7MM

• Total Eligible Patient Pool of Selected Indications for Radioligand Therapies in the 7MM

• Total Treated Cases in Selected Indications for Radioligand Therapies in the 7MM

The report evaluates the targeted patient population across selected indications and provides historical and forecasted assessments of eligible and treated patient pools across the United States, EU4, the United Kingdom, and Japan.

Scope of the Radioligand Therapies Market Report

• Study Period: 2022–2036

• Forecast Period: 2026–2036

• Geographies Covered: United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan

• Market Assessment: Total Market Size, Market Size by Therapies, and Market Size by Class

• Epidemiology Segmentation: Total cases of selected indications for radioligand therapies, total eligible patient pool of selected indications, and total treated cases in selected indications across the 7MM

• Key Companies Covered: Curium US, Eli Lilly, Point Biopharma, Fusion, AstraZeneca, Endocyte, Progenics Pharmaceuticals, AdvanCell Isotopes Pty Limited, and others

• Key Marketed Therapies Covered: LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN

• Key Emerging Therapies Covered: 177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, 225Ac-PSMA-617, 177Lu-NNS309, 177Lu-NeoB, AAA614, ESP359, 67Cu-SAR-BBN, 64Cu-SAR-BBN, ITM-11, 212Pb-NG001, CONV01-α, VMT-α-NET, VMT01, PSV359, CAM-FAP-Ac-225, 225Ac-SSO110, ATT001, NU101, NU201, and others.

• Clinical Development Assessment: The report analyzes Phase I, Phase II, and Phase III clinical trials, including clinical trial details, pharmacological action, collaborations, licensing agreements, regulatory approvals, patents, advantages and disadvantages, and recent developments.

• Market Analysis: Historical and forecasted market size, market share by therapy, market trends, treatment practices, unmet needs, drug uptake, competitive landscape, and market opportunities across the 7MM.

• Qualitative Analysis: SWOT analysis, KOL insights, treatment preferences, patient burden, accessibility, cost-effectiveness, and geographical accessibility.

• Market Access and Reimbursement: Country-specific accessibility and reimbursement scenarios, cost-effectiveness of approved therapies, patient assistance programs, and out-of-pocket cost considerations.

• Report Insights: Targeted patient pool, therapeutic approaches, pipeline analysis, market size, market trends, and existing and future market opportunities.

• Key Strengths: Eleven-year forecast, 7MM coverage, key cross-competition assessment, drug uptake, and key market forecast assumptions.

To know more about the clinical trials, emerging therapies, competitive landscape, and therapeutic assessment of Radioligand Therapies:View the Radioligand Therapies Market Report

Table of Contents